Live search
TopFind is fetching the latest matches for your search.
We reviewed 20 live results for biosimilars and narrowed them down to the 3 options that look most worth comparing first.
The strongest themes across this short list are Biosimilars and Immunosuppressant.
Source: Amgevita
Description
A group of TNF inhibitor monoclonal antibody biosimilars recently approved in Singapore. These are indicated for managing conditions such as rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis.
Best for
rheumatoid arthritis patients, Crohn’s disease treatment, psoriatic arthritis care and ulcerative colitis management
Rating
Source: Organon (Philippines) Incorporated
Description
A diverse portfolio focusing on reproductive health treatments, oncology biosimilars for breast cancer, and biological therapies for various inflammatory conditions.
Best for
women's reproductive health, breast cancer care, inflammatory disease treatment and specialist clinics
Rating
Source: Celltrion Healthcare
Description
Steqeyma is a biosimilar version of ustekinumab that has received approval from the Singapore Health Sciences Authority (HSA). It is indicated for treating inflammatory conditions such as plaque psoriasis and Crohn's disease, and is slated for subsidy under the Ministry of Health's Standard Drug List (SDL).
Best for
subsidized drug seekers in Singapore, long-term inflammatory care and HSA-approved biosimilar users
Rating
| Compare | Amgevita / Yuflyma / Hyrimoz (Adalimumab Biosimilars) | Women's Health and Biosimilar Medicines | Steqeyma (ustekinumab biosimilar) |
|---|---|---|---|
| Source | Amgevita | Organon (Philippines) Incorporated | Celltrion Healthcare |
| Description | A group of TNF inhibitor monoclonal antibody biosimilars recently approved in Singapore. These are indicated for managing conditions such as rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis. | A diverse portfolio focusing on reproductive health treatments, oncology biosimilars for breast cancer, and biological therapies for various inflammatory conditions. | Steqeyma is a biosimilar version of ustekinumab that has received approval from the Singapore Health Sciences Authority (HSA). It is indicated for treating inflammatory conditions such as plaque psoriasis and Crohn's disease, and is slated for subsidy under the Ministry of Health's Standard Drug List (SDL). |
| Best for | rheumatoid arthritis patients, Crohn’s disease treatment, psoriatic arthritis care and ulcerative colitis management | women's reproductive health, breast cancer care, inflammatory disease treatment and specialist clinics | subsidized drug seekers in Singapore, long-term inflammatory care and HSA-approved biosimilar users |
| Tags | |||
| Action | View Details | View Details | View Details |
| Rating |
If you want the most balanced option to start with, I recommend:
"Amgevita / Yuflyma / Hyrimoz (Adalimumab Biosimilars) from Amgevita."
I picked this because Offers modern biologic therapy options for several inflammatory conditions with recent HSA approval for biosimilar use.